title: [The importance of pathology in the German prostate cancer study PREFERE].
abstract: Prostate cancer is the most common carcinoma of elderly males and holds the third place in the ranking of cancer-specific mortality. However, total mortality rate of 3 % is low and half of the patients die from other diseases, which is for the most part due to significantly improved diagnostic methods and the increasing use of prostate-specific antigen (PSA) screening. This has led to a stage migration towards early tumor stages that are prognostically heterogeneous and require differentiated treatment. The German and European guidelines recommend four therapy options (i.e. radical prostatectomy, percutaneous irradiation, permanent seed implantation and active surveillance) for localized prostate cancer and from contemporary study data it is unclear which therapy is most beneficial. This will be the subject of the PREFERE trial, a prospective randomized multicentre trial which plans to recruit 7,600 patients and to observe them over a period of up to 17 years. The histopathological diagnosis of the primary biopsy plays a crucial role in the inclusion criteria, as this article outlines in detail.
authors: Institut für Pathologie, Universität Bonn, Sigmund-Freud-Strasse 25, Bonn, Germany. glen.kristiansen@ukb.uni-bonn.de
authors: G
authors: G
authors: Kristiansen
authors: M
authors: M
authors: Stöckle
authors: P
authors: P
authors: Albers
authors: H
authors: H
authors: Schmidberger
authors: P
authors: P
authors: Martus
authors: S
authors: S
authors: Wellek
authors: M
authors: M
authors: Härter
authors: R
authors: R
authors: Bussar-Maatz
authors: T
authors: T
authors: Wiegel
mesh_terms: D000368:Aged; D001706:Biopsy; D001707:Biopsy, Needle; D042241:Early Diagnosis; D005858:Germany; D006801:Humans; D008297:Male; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D011467:Prostate / Q000473:pathology; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000473:pathology* / Q000628:therapy*; D011867:Radioisotope Teletherapy; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D057832:Watchful Waiting
references: Eur Urol. 2009 May;55(5):1037-63
references: 19185977
references: J Clin Oncol. 2011 Sep 20;29(27):3669-76
references: 21825257
references: Eur Urol. 2013 Aug;64(2):193-8
references: 23522911
references: J Urol. 2010 Feb;183(2):433-40
references: 20006878
references: Radiother Oncol. 2007 Apr;83(1):3-10
references: 17321620
references: Virchows Arch. 2011 Aug;459(2):175-82
references: 21698392
references: Am J Surg Pathol. 2010 Jan;34(1):35-43
references: 19935058
references: Eur Urol. 2013 Aug;64(2):199-201; discussion 202-3
references: 23608669
references: J Clin Oncol. 2002 Aug 15;20(16):3376-85
references: 12177097
references: J Clin Oncol. 2010 Jan 1;28(1):126-31
references: 19917860
references: Strahlenther Onkol. 2010 Oct;186(10):531-4
references: 20890742
references: Nat Rev Urol. 2011 Mar;8(3):124-5
references: 21304508
references: JAMA. 2005 May 4;293(17):2095-101
references: 15870412
references: Histopathology. 2012 Jan;60(1):125-41
references: 22212082
references: J Urol. 2010 Jul;184(1):126-30
references: 20478583
references: Urologe A. 2010 Feb;49(2):216-20
references: 20180062
references: N Engl J Med. 2011 May 5;364(18):1708-17
references: 21542742
references: BJU Int. 2011 Jun;107(12):1956-62
references: 21044243
references: Am J Surg Pathol. 2005 Sep;29(9):1228-42
references: 16096414
references: J Clin Oncol. 2010 Jun 10;28(17):2810-6
references: 20439642
references: Eur Urol. 2011 Jan;59(1):61-71
references: 21056534
references: Radiother Oncol. 2004 Apr;71(1):29-33
references: 15066293
references: J Urol. 1983 Aug;130(2):283-6
references: 6876274
references: J Clin Oncol. 2005 Nov 10;23(32):8165-9
references: 16278468